Improving Health, Improving Lives
NHS Calderdale Clinical Commissioning Group Logo

Biosimilar Uptake (1819053)

1.Has an approach to Biosimilar uptake been discussed and agreed with:

The CCG governing body (Y/N) No

Area Prescribing Committee (Y/N) No

Relevant local provider organisation (Y/N) Yes

Relevant Sustainability and Transformation Partnerships (Y/N) No

2.Do you have a mechanism in place for identifying the date of patent expiry for originator biological medicines, and the possible launch date of individual biosimilar products ? (Y/N)

Yes

3.Have you identified the level of potential savings opportunity available to your health economy through the use of biosimilar medicines ? (Y/N)

Yes

4.Has your CCG accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding ? (Y/N)

Not applicable. The CCG is not a provider organisation and does not order, store or dispense medication.

5.If your CCG accepted or is it currently accepting FOC stock, please state “Yes” to any of following:

Brodalumab (Kyntheum)

Guselkumab (Tremfya)

Ixekizumab (Taltz)

Secukinumab (Cosentyx) in Psoriasis or Ankylosing Spondylitis or Psoriatic Arthritis

Not applicable – see 4 above

6. Has your Trust / CCG accepted or is it currently accepting the following list of drugs in

Tofacitinib (Xeljanz)

Baricitinib (Olumiant)

Golimumab (Simponi) in Rheumatoid Arthritis or Ulcerative Colitis

Certolizumab (Cimzia)

Apremilast (Otezla)

Tocilizumab (Ro Actemra)

Not applicable – see 4 above

7. If your Trust / CCG has not accepted manufacturer provision of free of charge drug stock, are there reasons for this ?

Not applicable – see 4 above

8. For how long is free of charge drug stock typically provided for each patient?

Not applicable – see 5 above

9. Are there any agreements in place between you the CCG and a Provider (eg Hospital Trust) that would enable savings in drug costs to be made ? (For example, Gainshare agreements where the benefits associated with more efficient us of medicines not reimbursed through national prices is shared between the Provider and the Clinical Commissioning Group party to the agreement.  This includes agreements for the switch to biosimilar products)

If “Yes”, then please provide the following details

Yes. Gainshare agreements are in place to support the switch to biosimilar products by the provider.

NHS Choices
NHS Constitution
NHS Constitution
Disability Confident Employer Badge

NHS Calderdale Clinical Commissioning Group: 5th floor, F Mill, Dean Clough, Halifax, HX3 5AX. Tel: 01422 307400

| Privacy Notice | Glossary of Terms | Work for us| Icons provided by Icons8| Free Stock Videos by Videezy | © NHS Calderdale CCG 2018 |

Translate »
Click to listen highlighted text!